Named Bioactive Compounds · Fermented/Probiotic
Fructooligosaccharides
Moderate Evidenceprebiotic4 PubMed Studies
Hermetica Superfood Encyclopedia
Fructooligosaccharides (FOS) are prebiotic fibers that resist digestion in the small intestine and selectively feed beneficial bacteria in the colon. They work by serving as substrate for Bifidobacteria and Lactobacilli, promoting gut health through improved microbial balance.
Fructooligosaccharides (FOS) are short-chain prebiotic carbohydrates consisting of 2-6 fructose molecules linked to a terminal glucose unit, naturally occurring in chicory root, onions, garlic, bananas, and asparagus. They are commercially extracted via hot water diffusion from chicory roots followed by purification, or synthesized from sucrose using fructosyltransferase enzymes.
A 2018 RCT in 38 infants with constipation showed 83.3% therapeutic success with FOS supplementation (PMID: 30388751). A 2024 meta-analysis of 17 RCTs confirmed FOS increases stool frequency and improves consistency across age groups (PMID: 39766936). A 2022 meta-analysis demonstrated significant increases in gut Bifidobacteria with greater effects after 4 weeks of supplementation.
Clinically studied doses range from 0.45 g/day (in pediatric supplements for 45 days) to 20 g/day (in water for adults with constipation for 30 days). Infant formulas used FOS with polymerization degree 2-6 for 4 weeks. Most studies used 100% FOS powder dissolved in water or added to food. Consult a healthcare provider before starting any new supplement.
Fructooligosaccharides (FOS) are short-chain carbohydrates composed of fructose units linked by β(2→1) glycosidic bonds, typically with a degree of polymerization (DP) of 2–8 units. Caloric contribution is approximately 1.5–2 kcal/g (significantly lower than digestible carbohydrates at 4 kcal/g) due to resistance to hydrolysis by human small intestinal enzymes. FOS are classified as soluble dietary fiber and function as prebiotics. They contain no significant protein, fat, vitamins, or minerals intrinsically. Key bioactive profile: inulin-type fructans including kestose (GF2), nystose (GF3), and fructosylnystose (GF4) as primary structural components. Upon colonic fermentation by resident microbiota (primarily Bifidobacterium and Lactobacillus species), FOS yield short-chain fatty acids (SCFAs) — predominantly acetate (50–60% of SCFA output), propionate (20–25%), and butyrate (15–20%) — at an estimated yield of approximately 1–2 mmol SCFAs per gram of fermented FOS. Butyrate production specifically supports colonocyte energy metabolism. SCFA-driven reduction in colonic pH (from ~6.8 to ~5.5–6.2) enhances ionization and solubility of divalent minerals, improving bioavailability of calcium by an estimated 20–58% and magnesium by approximately 10–25% as documented in intervention studies. FOS themselves are not a direct source of these minerals but act as bioavailability enhancers. Typical supplemental doses range from 2.5–10 g/day; doses above 10 g/day are associated with increased gastrointestinal side effects including bloating and flatulence. No significant fat-soluble or water-soluble vitamin content is present in isolated FOS preparations.
Fructooligosaccharides resist hydrolysis by human digestive enzymes due to β(2→1) fructosyl linkages, allowing them to reach the colon intact. Beneficial bacteria like Bifidobacterium and Lactobacillus utilize β-fructofuranosidase enzymes to metabolize FOS, producing short-chain fatty acids (SCFAs) including acetate, propionate, and butyrate. These SCFAs lower colonic pH, inhibit pathogenic bacteria growth, and improve intestinal barrier function.
A meta-analysis of 17 randomized controlled trials (PMID: 39766936) demonstrated that FOS supplementation significantly improves stool frequency and consistency in constipated individuals. Meta-analytic evidence shows FOS increases Bifidobacteria populations by 0.599 log10 cells/g (p<0.001). Most studies used doses ranging from 5-20g daily for 2-8 weeks, with consistent benefits observed across different populations including healthy adults and those with digestive disorders.
Fructooligosaccharides are generally well-tolerated with mild gastrointestinal side effects including bloating, flatulence, and abdominal discomfort, particularly at doses exceeding 10g daily. No significant drug interactions have been documented, though FOS may enhance mineral absorption including calcium and magnesium. Individuals with fructose malabsorption or irritable bowel syndrome should use caution as symptoms may worsen. Safety during pregnancy and lactation has not been established through clinical trials.
